301 related articles for article (PubMed ID: 29344954)
21. Usefulness and limitations of E-cadherin and β-catenin in the classification of breast carcinomas in situ with mixed pattern.
Gomes DS; Porto SS; Rocha RM; Gobbi H
Diagn Pathol; 2013 Jul; 8():114. PubMed ID: 23837653
[TBL] [Abstract][Full Text] [Related]
22. The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology.
Rakha EA; Gill MS; El-Sayed ME; Khan MM; Hodi Z; Blamey RW; Evans AJ; Lee AH; Ellis IO
Breast Cancer Res Treat; 2009 Mar; 114(2):243-50. PubMed ID: 18404368
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
[TBL] [Abstract][Full Text] [Related]
24. Expression patterns of beta-catenin in in situ and invasive breast cancer.
Karayiannakis AJ; Nakopoulou L; Gakiopoulou H; Keramopoulos A; Davaris PS; Pignatelli M
Eur J Surg Oncol; 2001 Feb; 27(1):31-6. PubMed ID: 11237489
[TBL] [Abstract][Full Text] [Related]
25. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization.
Jacobs TW; Pliss N; Kouria G; Schnitt SJ
Am J Surg Pathol; 2001 Feb; 25(2):229-36. PubMed ID: 11176072
[TBL] [Abstract][Full Text] [Related]
26. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
Renshaw AA; Gould EW
Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
[TBL] [Abstract][Full Text] [Related]
27. Lobular carcinoma in situ: diagnostic criteria and molecular correlates.
Sokolova A; Lakhani SR
Mod Pathol; 2021 Jan; 34(Suppl 1):8-14. PubMed ID: 33024303
[TBL] [Abstract][Full Text] [Related]
28. The Pathologic Finding of Combined Lobular Carcinoma
Jean-Louis CJ; Masdon J; Smith B; Battles O; Dale P
Am Surg; 2017 May; 83(5):482-485. PubMed ID: 28541858
[TBL] [Abstract][Full Text] [Related]
29. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
30. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions.
Andrade VP; Ostrovnaya I; Seshan VE; Morrogh M; Giri D; Olvera N; De Brot M; Morrow M; Begg CB; King TA
Breast Cancer Res; 2012 Jul; 14(4):R103. PubMed ID: 22776144
[TBL] [Abstract][Full Text] [Related]
31. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas.
Kovács A; Dhillon J; Walker RA
Mol Pathol; 2003 Dec; 56(6):318-22. PubMed ID: 14645693
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
De Leeuw WJ; Berx G; Vos CB; Peterse JL; Van de Vijver MJ; Litvinov S; Van Roy F; Cornelisse CJ; Cleton-Jansen AM
J Pathol; 1997 Dec; 183(4):404-11. PubMed ID: 9496256
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathologic observation of carcinomas arising in fibroepithelial neoplasms of the breast].
Yang G; Guo L; Jin H; Li J; Ding H
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):437-41. PubMed ID: 25327790
[TBL] [Abstract][Full Text] [Related]
34. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma?
Bagaria SP; Shamonki J; Kinnaird M; Ray PS; Giuliano AE
Ann Surg Oncol; 2011 Jul; 18(7):1845-51. PubMed ID: 21287281
[TBL] [Abstract][Full Text] [Related]
35. Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma.
Shamir ER; Chen YY; Krings G
Mod Pathol; 2020 Jun; 33(6):1078-1091. PubMed ID: 31907376
[TBL] [Abstract][Full Text] [Related]
36. Salivary Duct Carcinoma With Rhabdoid Features-No or Aberrant Expression of E-cadherin and Genetic Changes in CDH1: Immunohistochemical and Genetic Analyses of 17 Cases.
Kusafuka K; Yamada H; Ishino K; Maeda M; Yamanegi K; Baba S; Ohuchi T; Inagaki H; Yamamoto H; Iwasaki T; Tsuchiya C; Sugimura H; Suzuki M
Am J Surg Pathol; 2021 Apr; 45(4):439-449. PubMed ID: 33538422
[TBL] [Abstract][Full Text] [Related]
37. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast.
Buerger H; Simon R; Schäfer KL; Diallo R; Littmann R; Poremba C; van Diest PJ; Dockhorn-Dworniczak B; Böcker W
Mol Pathol; 2000 Jun; 53(3):118-21. PubMed ID: 10897329
[TBL] [Abstract][Full Text] [Related]
38. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias.
Bratthauer GL; Moinfar F; Stamatakos MD; Mezzetti TP; Shekitka KM; Man YG; Tavassoli FA
Hum Pathol; 2002 Jun; 33(6):620-7. PubMed ID: 12152161
[TBL] [Abstract][Full Text] [Related]
39. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas.
Rieger-Christ KM; Pezza JA; Dugan JM; Braasch JW; Hughes KS; Summerhayes IC
Mol Pathol; 2001 Apr; 54(2):91-7. PubMed ID: 11322170
[TBL] [Abstract][Full Text] [Related]
40. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
